Protagenic Therapeutics, Incnew Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OQB
Bigger Capital Fund, LP and its affiliates have reported a complete divestment of their beneficial ownership in Protagenic Therapeutics, Inc., now holding 0% of common stock.
OQB
Bigger Capital Fund L.P., along with its general partner Bigger Capital Fund GP, LLC and managing member Michael Bigger, has disclosed a beneficial ownership of 5.75% in Protagenic Therapeutics, Inc., totaling 50,000 shares of common stock.
OQB
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 3.41% Passive Stake in Protagenic Therapeutics
Armistice Capital, LLC and Steven Boyd have reported a 3.41% beneficial ownership stake in Protagenic Therapeutics, Inc., holding 240,000 shares as of December 31, 2024, as a passive investment.